Correlations of tmTNF-α expression with clinical features of AML
| Characteristics . | Cases . | Expression (%) of tmTNF-α (mean ± SEM) . | P . |
|---|---|---|---|
| AML (subtype) | .0711 | ||
| M1 | 4 | 17.33 ± 11.18 | |
| M2 | 14 | 48.22 ± 11.01 | |
| M3 | 14 | 46.48 ± 9.762 | |
| M4 | 5 | 55.5 ± 19.8 | |
| M5 | 28 | 68.26 ± 6.498 | |
| Age (y) | .9394 | ||
| ≥60 | 12 | 55.98 ± 11.83 | |
| <60 | 57 | 55.06 ± 4.93 | |
| BM blasts | .2987 | ||
| >Median | 59.88 ± 6.155 | ||
| ≤Median | 50.41 ± 6.636 | ||
| BM CD34+% (exclude M3) | <.05 | ||
| >Median | 67.9 ± 6.799 | ||
| ≤Median | 46.29 ± 7.155 | ||
| White cell count (×10−3/mm3) | .8774 | ||
| >Median | 55.93 ± 6.795 | ||
| ≤Median | 54.52 ± 6.094 | ||
| Risk status*(cytogenetic abnormalities) | .1589 | ||
| Favorable | 21 | 42.95 ± 8.022 | |
| Intermediate | 46 | 59.81 ± 5.513 | |
| Adverse | 2 | 78.43 ± 21.17 | |
| Risk status*(exclude M3) | |||
| Favorable | 4 | 5.67 ± 3.579 | |
| Intermediate | 41 | 55.91 ± 5.874 | <.05† |
| Adverse | 10 | 84.45 ± 5.274 | <.001† |
| Risk status*(M3) | .4562 | ||
| Favorable/intermediate | 4 | 34.4 ± 19.15 | |
| Adverse | 10 | 51.31 ± 11.61 | |
| Extramedullary infiltration | <.05 | ||
| Yes | 17 | 70.78 ± 8.157 | |
| No | 47 | 48.95 ± 5.549 | |
| Gene mutation | .72 | ||
| DNMT3A | 9 | 54.3 ± 11.47 | |
| C-KIT | 3 | 67.26 ± 32.33 | |
| CEBPA | 8 | 42.31 ± 13.98 | |
| FLT3-ITD | 13 | 64.74 ± 9.929 | |
| NPM1 | 7 | 54.01 ± 15.44 |
| Characteristics . | Cases . | Expression (%) of tmTNF-α (mean ± SEM) . | P . |
|---|---|---|---|
| AML (subtype) | .0711 | ||
| M1 | 4 | 17.33 ± 11.18 | |
| M2 | 14 | 48.22 ± 11.01 | |
| M3 | 14 | 46.48 ± 9.762 | |
| M4 | 5 | 55.5 ± 19.8 | |
| M5 | 28 | 68.26 ± 6.498 | |
| Age (y) | .9394 | ||
| ≥60 | 12 | 55.98 ± 11.83 | |
| <60 | 57 | 55.06 ± 4.93 | |
| BM blasts | .2987 | ||
| >Median | 59.88 ± 6.155 | ||
| ≤Median | 50.41 ± 6.636 | ||
| BM CD34+% (exclude M3) | <.05 | ||
| >Median | 67.9 ± 6.799 | ||
| ≤Median | 46.29 ± 7.155 | ||
| White cell count (×10−3/mm3) | .8774 | ||
| >Median | 55.93 ± 6.795 | ||
| ≤Median | 54.52 ± 6.094 | ||
| Risk status*(cytogenetic abnormalities) | .1589 | ||
| Favorable | 21 | 42.95 ± 8.022 | |
| Intermediate | 46 | 59.81 ± 5.513 | |
| Adverse | 2 | 78.43 ± 21.17 | |
| Risk status*(exclude M3) | |||
| Favorable | 4 | 5.67 ± 3.579 | |
| Intermediate | 41 | 55.91 ± 5.874 | <.05† |
| Adverse | 10 | 84.45 ± 5.274 | <.001† |
| Risk status*(M3) | .4562 | ||
| Favorable/intermediate | 4 | 34.4 ± 19.15 | |
| Adverse | 10 | 51.31 ± 11.61 | |
| Extramedullary infiltration | <.05 | ||
| Yes | 17 | 70.78 ± 8.157 | |
| No | 47 | 48.95 ± 5.549 | |
| Gene mutation | .72 | ||
| DNMT3A | 9 | 54.3 ± 11.47 | |
| C-KIT | 3 | 67.26 ± 32.33 | |
| CEBPA | 8 | 42.31 ± 13.98 | |
| FLT3-ITD | 13 | 64.74 ± 9.929 | |
| NPM1 | 7 | 54.01 ± 15.44 |
Differences between 2 groups were analyzed by the Student t test. Although differences are compared among 3 or more groups, P values are calculated by 1-way analysis of variance.
Risk status stratification is according to National Comprehensive Cancer Network (NCCN) guidelines (2012).
As compared with favorable.